

PROGRAMME Workshop 8 October 2019, Brussels

Maintaining European scientific excellence and global leadership in TB Vaccine R&D EU funded collaborative research and innovation

Impact of 3 EU funded TB vaccine Research and Innovation projects on the global TB vaccine pipeline

This meeting brings together scientists, policy makers, funders and other key stakeholders in TB vaccine research and innovation (R&I). The results and impact of three H2020 TB projects (TBVAC2020, EMI-TB and STriTuVaD) on the TB vaccine field and the TB vaccine pipeline will be presented.

Meeting participants will be asked to contribute to priority policy relevant recommendations as to how the collaborative research effort that underpins these results, can be taken forward in the next two years and be imbedded in FP9.

These recommendations will focus on the:

- High-level R&I elements, areas and relevant technical infrastructures of TB vaccine R&I consortia
- Structure and composition of collaborative TB vaccine R&I consortia
- Funding instruments for collaborative R&I

Programme:

9.30 Coffee/tea and registration

9.45 – 10.00 Opening and introduction by the chair: Objectives of the workshop: Achievements EC H2020 and challenges for EC Europe Horizon related to TB vaccine R&D projects – EC policy officer, Hannu Laang

Session 1. Impact of European collaborative research & innovation on the global TB vaccine pipeline

10.00 – 10.45 TBVAC2020: Impact achieved on the global TB vaccine pipeline

- i. The consortium (a brief history, collaborative research working model, current status TB vaccine pipeline) - *Stefan Kaufmann, MPIIB*
- ii. TBVAC2020 impact and results
 - Discovery of TB vaccine candidates – *Olivier Neyrolles, CNRS*
 - Evaluation and prioritization of candidates and Impact on the TB vaccine pipeline - *Ann Rawkins, PHE*
 - TB Biomarkers - *Tom Ottenhoff, LUMC*

10.45 – 11.10 EMI-TB: Eliciting Mucosal Immunity in TB – *Rajko Relic, St Georges University*

- Mucosal vaccine development in the Eliciting Mucosal Immunity in TB project - *Rajko Relic, St Georges University*

- Mechanisms and correlates of protective immunity to tuberculosis in animals and humans
- *Africa Gonzalez Fernandez*
- 11.10 – 11.35 STriTuVaD: In Silico Trial for Tuberculosis Vaccine Development – *Epifanio Fichera*
 - The Impact of STriTuVaD computational platform on TB vaccine pipeline: improvements and future implications - *Francesco Pappalardo, University di Catania*
 - Improving TB chemotherapy with therapeutic vaccination – *Pere-Joan Cardona, IGTP*
- 11.35 - 11.55 Conclusions and upcoming challenges for TB vaccine collaborative research and consortia, - *Stefan Kaufmann, MPIIB*

11.55- 12.55 LUNCH

Session 2. Towards recommendations to sustain and strengthen collaborative R&I to maintain European scientific excellence and global leadership in TB vaccine R&I.

Opening by the chair – Nick Drager, TBVI

13.00 – 13.45 Panel 1. High-level R&I elements, areas and relevant technical support infrastructures and processes of TB vaccine R&I consortia

Driving research and innovation through lessons learned in the past years in TB vaccine R&D and clinical developments. Applying an evidence based and transparent process in portfolio assessment.

Chair: Gerald Voss

Panel members: Helen Mc Shane, Rajko Relic, Frank Verreck, Flora Musuamba Thsinanu

13.45 – 14.30 Panel 2. Composition/structure (incl. partners and stakeholders) of collaborative TB vaccine R&I consortia (which partners and structures are needed to deliver the key R&I content).

Opportunities and ways to strengthening collaborative R&I consortia and build on EU excellence to advance the TB vaccine field.

Chair: Hazel Dockrell

Panel members: Tonnie Rijkers, Olga Rue, Sarah Ashwood, Georges Thiry

14.30 – 15.15 Panel 3. Funding instruments for collaborative R&I.

A long-term vision with appropriate and sustainable funding instruments is needed for TB vaccine R&I to accelerate promising vaccine candidates and ensure continuous innovation and diversity in the TB vaccine pipeline.

Chair: Beatrice De Vos

Panel Members: Hannu Laang, Ole Olesen, Martin Broadstock

15.15 - 15.30 Conclusions of the panel discussions and priorities, next steps – Nick Drager